We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
- Authors
Batchelor, Tracy T; Gilbert, Mark R; Supko, Jeffrey G; Carson, Kathryn A; Nabors, Louis B; Grossman, Stuart A; Lesser, Glenn J; Mikkelsen, Tom; Phuphanich, Surasak; NABTT CNS Consortium
- Abstract
The primary objective of this study was to determine the proportion of patients exhibiting a radiographic response in a cohort of patients with recurrent malignant glioma who were treated with irinotecan. Secondary objectives were to determine progression-free survival, overall survival, and toxicity. The trial was terminated after the first 18 patients were enrolled in this multicenter, 2-stage, phase 2 study. Twelve patients received concurrent enzyme-inducing antiepileptic drugs, and 6 did not. Each cycle consisted of a 90-min i.v. infusion of irinotecan every week for 4 consecutive weeks, followed by 2 weeks off. One patient had a complete response, 5 patients had stable disease, 5 patients had radiographic progression, 6 patients were removed from the study because of toxicity, and 1 patient refused further therapy and was removed from the study. The response rate in this study was 6% (1/18), and 28% (5/18) of these patients progressed while receiving irinotecan. Dose-limiting toxicities consisted of diarrhea in 5 patients, neutropenia in 1 patient, infection in 1 patient, and respiratory failure in 1 patient. Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations.
- Publication
Neuro-oncology, 2004, Vol 6, Issue 1, p21
- ISSN
1522-8517
- Publication type
Journal Article
- DOI
10.1215/s1152851703000218